<DOC>
	<DOCNO>NCT02469181</DOCNO>
	<brief_summary>The purpose study evaluate impact ERT LV diastolic function flow patient Fabry 's cardiomyopathy use diastolic stress echocardiography , LV vortex flow CMR .</brief_summary>
	<brief_title>Impact Enzyme Replacement Therapy Cardiac Function Patients With Fabry 's Cardiomyopathy ( RECAFTURE Trial )</brief_title>
	<detailed_description>1 . Objectives -The purpose study evaluate impact ERT LV diastolic function flow patient Fabry 's cardiomyopathy use diastolic stress echocardiography , LV vortex flow CMR . 2 . Primary / Secondary Endpoint 1 ) Primary endpoint - Changes peak exercise E/E ' diastolic stress echocardiography ( RECAP-F STRESS trial ) LV vortex flow parameter ( RECAP-F FLOW trial ) 1 year follow . 2 ) Secondary endpoint - Changes extracellular volume CMR ( T1 map ) 1 year follow ( RECAP-F trial ) ② Evaluation degree rest LV diastolic function ③ Other echo-parameters ; LV mass index baseline , 1 year follow , reduction peak exercise E/E prime 1 year follow - Changes quality life use questionnaire ⑤ Change peak VO2 , exercise time , AT diastolic stress echocardiography 1 year follow ⑥ Change T1 baseline ( myo , m ) &amp; T1 baseline ( blood , m ) T1 postcontrast ( myo , m ) &amp; T1 baseline ( blood , m ) CMR 3 . Study Methods 1 ) Study Design : 28 patient newly diagnose genetically confirm Anderson-Fabry 's disease undergo diastolic stress echocardiography , LV vortex flow analysis , cardiac MRI enzyme replacement therapy ( ERT ) ( baseline study ) 1 year treatment agalsidese beta dose 1mg/kg ( follow-up study ) . 2 ) Study procedure : Examinations describe do ERT 1 year later</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Patients age 20~75 year Fabry 's disease confirm enzyme assay gene study All patient LV hypertrophy 2D echocardiography ( end diastolic septum posterior wall thickness ≥12mm ) Patients provide write , inform consent participate study Contraindication agalsidase beta enzyme replacement treatment Patients perform supine bicycle stress echocardiography , contrast echocardiography cardiac MRI Hemodynamically significant valvular heart disease arrythmias History acute myocardial infarction congestive heart failure reduce LV ejection fraction le 35 % CVA prior 6 month Scheduled plan surgery next 6 month Chronic liver cirrhosis Allergy contrast agent ( Definity® , Lantheus Medical Imaging , North Billerica , MA , USA )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>